On 2026-09-29, BofA Securities raised its JNJ price target to $278.
BofA Securities 于 2026-09-29 将 JNJ 目标价上调至 $278。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
HSBC raises JNJ target to $320 from $290HSBC 上调目标价 强生 (JNJ)：$290 → $320
Rating Change · September 10, 2026评级变动 · 2026/9/10
JNJ regulatory decision: FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsJohnson & Johnson（JNJ）的 产品 获美国 FDA 许可或批准
Material Company Event · August 24, 2026公司公告 · 2026/8/24
Duato Joaquin sells $32.2M of JNJDuato Joaquin 内部减持 强生 (JNJ) $32.2M
Insider Sale · August 14, 2026内部人减持 · 2026/8/14
